Artera Secures New York State License, Expanding Nationwide Access to Its AI-Driven Prostate Cancer Test

Artera Secures New York State License for ArteraAI Prostate Test, Enabling Nationwide Access San Francisco-based Artera, the pioneer in multimodal artificial intelligence (MMAI)-based cancer diagnostics, announced today that it has secured a laboratory permit from the New York State Department of Health. This license marks a significant milestone, making the ArteraAI Prostate Test available to one of the largest healthcare markets in the United States and extending its reach to patients nationwide. The ArteraAI Prostate Test stands out as the only diagnostic tool included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology that can predict therapy benefits and forecast long-term outcomes for localized prostate cancer. Effective June 4, clinicians and patients in New York will have access to these data-driven insights, which can help personalize treatment decisions and improve outcomes. "Securing the New York State laboratory license is a major achievement for Artera," said Andre Esteva, CEO and co-founder of the company. "Each year, over 15,000 men in New York alone are diagnosed with prostate cancer, according to the New York State Department of Health. Increasing access to AI-powered precision medicine tools has been a core mission since the company's inception, and I am proud that our team has achieved this goal in record time." To grant the license, New York State inspectors conducted a thorough evaluation of Artera’s laboratory, reviewing staff qualifications, equipment, facilities, safety programs, and management practices to ensure the highest standards of care. This accreditation builds upon the College of American Pathologists (CAP) accreditation and the State of California license that Artera obtained in August and October of last year, respectively. These certifications collectively highlight Artera’s dedication to quality and patient safety. Himanshu Nagar, MD, Director of Genitourinary Cancer at Memorial Sloan Kettering Cancer Center, expressed his approval: "We are excited about the availability of the ArteraAI Prostate Test in New York. This test enhances our current biomarkers by integrating advanced multimodal AI analysis of digital pathology and clinical data. It provides a precise risk stratification, enabling us to tailor treatment plans more accurately, ensure patients receive the most effective therapy, and reduce unnecessary interventions." Artera’s cutting-edge approach involves using a proprietary algorithm to analyze digital images from a patient’s biopsy alongside their clinical data. This comprehensive analysis helps determine the patient's prognosis and predicts the effectiveness of specific therapies. The test has undergone rigorous validation using multiple Phase 3 randomized trials, supporting its reliability and clinical utility. As part of its commitment to high-quality diagnostics, Artera’s laboratory is CLIA-certified and CAP-accredited. Patients and clinicians can order the ArteraAI Prostate Test online through the company’s website, Artera.ai, and it is processed at Artera’s facility in Jacksonville, Florida. Recent advancements in the ArteraAI Prostate Test have further refined its capabilities, offering enhanced insights for higher-risk patients. These improvements were highlighted at the Best of ASCO 2025 conference, where the company presented compelling validation data. For more information about Artera and its suite of precision medicine solutions, visit Artera.ai. About Artera Artera is a leading precision medicine company focused on developing AI tests to customize cancer therapy. The ArteraAI Prostate Test is the first and only tool of its kind to provide both prognostic and predictive results for localized prostate cancer, integrating digital pathology and clinical data to optimize treatment plans.